This article is a short review of vasoactive drugs which are in use in todays clinical practice. In the past century, development of vasoactive drugs went through several phases. All of these drugs are today divided into several groups, depending on their place of action, pharmacological pathways and/or effects on target organ or organ system. Hence, many different agents are today in clinical practice, we have shown comparison between them. These agents provide new directions in the treatment of cardiovascular compromise, suggesting that the primary goal of therapy is to produce a vasodilatory effect of the circulation rather than to reverse hemodynamic failure by using inotropic agents, with their inherent risks and side effects.
Key words: vasoactive agents, inotropic agents, levosimendan, phosphodiesterase III inhibitors
Vasoactive agents are a group of bioactive chemicals, which change vasomotor tone through their influence on various peripheral receptors. Most of these agen-ts have inotropic effects (e.g. norepinephrine) as they bind with receptors positioned on the surface of the myocardium. Some pharmacologic agents are difficult to classify as their effects overlap, however all vasoactive drugs affect stroke volume and heart rate. This determines cardiac output and, as a consequence, overall cardiovascular function.
In the ideal situation, inotropic drugs would only have effects directly on myocardial cells, without simultaneous stimulation of other receptors. As one quickly learns, such is not the case with many of our most important vasoactive agents. Some inotropic agents such as dopamine (depending on the dose) provoke vasoconstriction while other such agents, like isoprenaline, cause vasodilatation.
Pure vasoconstrictors produce arterial wall constriction by stimulation of a-adrenergic receptors (e.g. phenylephrine) or by stimulating V1a receptors (e.g. vasopresine) on the vascular endothelial surfaces.
Pure vasodilators, on the other hand, are classified according to their predominate effect on the arteries (e.g. hydralazine), veins (e.g. nitroglycerine), or both arterial and venous (e.g. nitropruside) vessels. The main favorable result of hydralazine and nitropruside is a reduction of cardiac afterload and an increase in cardiac output. The main effect of nitroglycerine is achieved by venodilatation, which decreases preload and consequently cardiac output.
In 1908, Sir James McKenzie first des-cribed “low cardiac output syndrome”. Clinically, this syndrome results in global hypoperfusion, whose treatment requ-ires inotropic support by vasoactive medications, or mechanical intervention to support and improve cardiac work. In the early 1900s the mainstay of cardiac treatment was digitalis with the addition of a salt reduced diet. Accumulated fluids within pleural and peritoneal spaces were eliminated by mechanical means or by drainage. The use of diuretics was instituted during the 1920s. The treatment of congestive heart failure entered a second phase in the 1950s, when vasodilators were introduced into the physicians’ therapeutic armamentarium. With the introduction of the inotropic agents in the 1980s, a third great period in the therapy of heart failure had begun.
Using the pharmacokinetics and pharmacodynamics of many inotropic agents, Lehtonen was able to categorize them into two basic groups: cAMP dependent (Table 1), and cAMP independent (Table 2) (1).
The cAMP dependent group consists of those agents, which increase production of cAMP by stimulating adrenergic receptors (adrenergic and dopaminergic agonists) or by decreasing cAMP degradation by inhibiting phosphodiesterase activity (phosphodiesterase III inhibitors). In contrast, the groups of inotropic agents, which are in the cAMP independent group, are inhibitors of Na+-K+-ATPase (digoxin), potassium channel inhibitors (vesnarinon), agonists of ß- adrenergic receptors (phenylephrine), and include the calcium salts. The agents in this latter group affect ionic pumps and regulate the concentration of intracellular calcium (Table 3).
The catecholamine inotropic agents were among the earliest vasoactive agents and remain important and useful today although there can be some negative consequences of their use (Table 4). A major side effect is an increase in myocardial oxygen consumption. Furthermore, it is well established that during dopamine administration its effectiveness diminishes significantly as administration continues beyond 48 hours. This same effect has been seen after 90 hours with dobutamine. The most important component to explain the decreased effectiveness of inotropic agents is the functional condition of the b-adrenergic receptors. Today, there are many known conditions which change the density and responsiveness of b-adrenergic receptors. Such conditions, in fact, change the relationship within subgroups of b-adrenergic receptors in myocardium, from 80% b1: 20% b2 changing in 60% b1: 40% b2 (Table 5) (2).
Phosphodiesterase III inhibitors produce their effects independently of b-adrenergic receptors. They are a useful class of agents that can be employed in various therapeutic settings. They are a non-specific heterogeneous group of agents. All three phosphodiesterase fractions are physiologically active. They have strong chronotropic effects, and therefore should be avoided in clinical practice when an inotropic agent is needed. Specific inhibitors of this class of agents are divided into the two groups (Table 6) (2).
There is also a group of vasoactive agen-ts that exhibit an inotropic effect, but in addition, also have a vasodilator effect. Opie grouped these agents into a unique class, the inodilators (Table 7) (3).
A lack of tachyphylaxis and tachycardia, and being independent of b-adrenergic receptor conditions, gives a clinical advantage to this group of agents, when comparing them with the catecholamines (Table 8).
Furthermore, these agents have a very important myocardial effect, called the lusitropic effect, which was introduced into clinical terminology by Smith and Katz in 1986. Coining this term, the authors wanted to emphasize the role of diastolic dysfunction (4) during heart failure. All agents, which improve diastolic function, primarily by decreasing the actin-myosin overlap during diastole, are deemed to have a positive lusitropic effect.
Numerous adverse effects and an in-creased mortality are the reasons why many clinicians are often unsuccessful with the inotropic agents presently in use. New therapeutic agents have been developed in the last few years to assist the clinician in the stabilization, support and treatment of cardiovascular disease (Table 9).
One of the newest groups of inotropic agents (Table 10) is a group of agents, which increase the affinity of myofibrils for calcium and are called calcium sensitizers. Calcium sensitizers are the newest heterogeneous group of inotropic agents. The best known representatives of this group are levosimendan and pimobendan. Positive inotropic effects of levosimendan are achieved by its binding to troponin C and calcium, thereby stabilizing the tropomyosin molecule and prolonging the duration of actin-myosin overlap without a change in the net concentration of intracellular calcium. The vasodilatory effect of levosimendan is reached through activation of ATP-dependent potassium channels. This leads to a decrease in both afterload and preload, increased coronary blood flow and a resultant anti-ischemic effect. Levosimendan is therefore categorized as an anti-ischemic inotropic agent (5). Additionally, the incidence of arrhythmias is extremely low, there is no development of tolerance to its pharmacological effects, and the simultaneous administration of b-blockers and calcium channels blockers does not produce serious adverse effects.
In two large randomized studies, RUSSLAN and LIDO, it was documented that positive hemodynamic effects and a lower mortality was seen in patients who received levosimendan in comparison to patients who received dobutamine or placebo (6, 7). Also, there is much interest in levosimendan administration in patients with open-heart surgery, especially in those with off-pump procedure (8-10).
There are three types of natriuretic brain peptides. The A and B types are located in the atria and ventricles of the heart, and the C type is located in endothelial cells. B-natriuretic peptide has a spectrum of physiologic effects of clinical importance, which include reduction of both pre- and afterload along with diuretic and natriuretic effects (Table 11). The serum level of B-natriuretic peptide is directly correlated with the degree of chronic heart failure. Because of this, it has been added to the diagnostic protocol of the European Cardiology Association and to the protocol of congestive heart failure treatment as well (11).
Nesiritide is an exogenous recombinant B-natriuretic peptide with the same pharmacological profile. There have been nine clinical studies conducted using nesiritide involving over nine hundred patients. Significant, positive clinical effects have been documented.
Endothelin is a strong vasoconstrictor. There are two types of receptors to which it attaches. The ETa receptors are located in the vessel’s smooth muscles cells and the ETb receptors are located on the endothelial surfaces. Stimulation of the receptors by endothelin produces increased vascular tonus and progression of arteriosclerosis in subjects with coronary artery disease. Inhibition of endothelin function results in better hemodynamics, heart remodeling and a decreased proliferation of smooth muscles in blood vessel walls. In the RITZ study, and the VERITAS study, involving almost 1500 patients (13), favorable hemodynamic effects (a lowering the systemic blood pressure, and increase of cardiac index) were measured but without significant clinical improvement and or a reduction in mortality (4, 5, 12).
Arginin-vasopresine is an endogenous nonapeptide. It stimulates V1a receptors and produces vasoconstriction. At the same time stimulation of V2 receptors produces an antidiuretic effect. By these mechanisms vasopresine plays an important role in fluid homeostasis. It plays an important therapeutic role in states of refractory vasodilatation, in which patients are unresponsive to catecholamine vasoconstrictive therapy (14). Vasopresine has also a place in cardiopulmonary resuscitation procedures (15). In the animal model, it has shown better effects on circulation in the splanchnic region in comparison with norepinephrine (16).
Table 1. cAMP dependent inotropic agents
|phosphodiesterase III isoenzime inhibitors
derivate of biperidine – amrinone, milrinone
derivate of imidazolone – enoximone, piroximone
Table 2. cAMP independent inotropic agents
|potassium channels inhibitors
|agonists of α- adrenergic receptors
Table 3. Older therapeutic medications
|OLDER THERAPEUTIC MEDICATIONS|
|NOTE: treatment of acute heart failure did not change for decades
catecholamine inotropic agents
|Despite acute hemodynamic improvement, inotropic agents often increased mortality
Table 4. Adverse effects of catecholamine administration
|ADVERSE EFFECTS OF CATECHOLAMINE ADMINISTRATION|
|increase in oxygen consumption|
|increased risk of sudden cardiac death|
|difficulty during beta-blocker administration|
|Dependency on the functional condition of beta-adrenergic receptors|
Table 5.Conditions that alter receptor density and affect response to catecholamines
|CONDITIONS THAT ALTER RECEPTOR DENSITY AND AFFECT RESPONSE TO CATECHOLAMINES|
|CONDITION||RECEPTOR DENSITY CHANGE|
|congestive heart failure||(heart)*|
|sepsis||(-) > (liver, vasculature)|
|myocardial ischemia||(-) beta, (+)> (heart)|
|asthma||(-) beta (lungs leukocytes)+|
|cystic fibrosis||(-) beta (leukocytes)|
|agonist administration||(-) >, beta (heart, platelets, leukocytes)|
|antagonists administration||(+) >, beta (heart, platelets, leukocytes)|
|hyperthyroidism||(+) beta (heart)|
|hypothyroidism||(-) beta (heart)|
|glucocorticoids||(+) beta (heart, leukocytes)|
Legend: *beta -adrenergic receptors are decreased in severe heart failure; + if on beta – agonists therapy for asthma; (+) – increased; (-) – decreased. Modified from: Zaritsky A, Eisenberg MG. Ontogenetic consideration in the pharmacotherapy of shock. In: Chernow B, Shoemarker WC, eds. Critical Care: State of the Art. Fullerton, CA: Society of Critical Care Medicine; 1986;7:485-534
Table 6. Phosphodiesterase iii inhibitors
|PHOSPHODIESTERASE III INHIBITORS (PDE III)|
derivates of biperidine – amrinone, milrinone
derivates of imidazolone – enoximone, piroximone
Table 7. Effects of phosphodiesterase III inhibitors
|EFFECTS OF PHOSPHODIESTERASE III INHIBITORS|
|PLATELETS AND LEUKOCYTES||metabolic effect|
Table 8. Advantages of phosphodiesterase III inhibitors
|ADVANTAGES OF PHOSPHODIESTERASE III INHIBITORS|
|myocardial – positive lusitropic effect|
|independent of the functional condition of adrenergic receptors|
|lack of tachyphylaxis|
|lack of tachycardia|
Table 9. New therapeutic goals
|NEW THERAPEUTIC GOALS|
|AGENT||EFFECT||MECHANISM OF ACTION|
|ISDN – high doses||venous and arterial vasodilatation||synthesis of NO|
|Tezosentan||arterial vasodilatation||blockade of endothelin receptors|
|Nesiritide||arterial vasodilatation||decrease of preload, afterload, diuresis|
|Levosimendan||inotropic, vasodilatation||binding for troponin C, activation of potassium channels|
Table 10. Newer inotropic agents
|NEWER INOTROPIC AGENTS|
natriuretic brain peptide – nesiritide
Table 11. B-type natriuretic peptide (bnp) – physiologic effects
|B-TYPE NATRIURETIC PEPTIDE (BNP) – PHYSIOLOGIC EFFECTS|
lack of tachycardia
decrease endothelin 1
inhibit RAA axis
decrease of epinephrine level
diuresis and natriuresis
increased filtration fraction
GFR effect variable
CI-cardiac index; RAA-renin-angiotensin-aldosterone system; GFR-glomerular filtration rate
Historically, the catecholamines inotropic agents were first line medications used in the treatment of cardiovascular compromise, but their benefits were often overshadowed by major complications, such as increased mortality. The introduction of many newer agents in newer classes, such as those which produce their effects independently of b-receptor functionality (e.g. phosphodiesterase III inhibitors), or do not change the intracellular calcium values (e.g. calcium sensitizers), represent safer, better choices for treatment. They also establish new directions in the treatment of cardiovascular compromise, suggesting that the primary goal of therapy is to produce a vasodilatory effect of the circulation rather than to reverse hemodynamic failure using inotropic agents, with their inherent risks and side effects.
01. Lehtonen AE, Antila S, Pentikainen PJ. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet 2004;43:187-203.
02. Priebe HJ. Vasoactive drugs (IARS Review Course Lectures). Anesth Analg 2004;64:79-83.
03. Opie LH, Chatterjee K, Gersh BJ. Drug for heart 2nd edition. Orlando, Florida: Grune Stratonn; 1986, pp 306-309.
04. Smith VE, Katz AM. Inotropic and lusitropic abnormalities as the basis for heart failure. Heart Failure 1987;3:55-65.
05. Lehtonen LA. Levosimendan: a parenteral calcium-sensitizing drug with additional vasodilatatory properties. Expert Opin Investing Drugs 2001;10:955-970
06. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI; RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double blind study (RUSSLAN). Eur Heart J 2002;23:1422-32
07. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
08. Barisin S, Husedzinovic I, Sonicki Z, Bradic N, Barisin A, Tonkovic D. Levosimendan in Off–Pump Coronary Artery Bypass; A Four – times Masked Controlled Study. J Cardivasc Pharmaco 2004;44:703-708.
09. Husedzinovic I, Bradic N, Barisin S. Levosimendan-hemodynamic support during off-pump coronary artery bypass graft surgery. Intensive Care Med 2005;31(suppl 1):S 97.
10. Husedžinović I, Barišin S, Bradić N, Barišin A, Sonicki Z, Milanović R. Levosimendan as a new strategy during off – pump coronary artery bypass grafting: Double – blind randomized placebo – controlled trial. Croat Med J. 2005;46:950-6.
11. Rodeheffer RJ. Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004?. J Am Coll Cardiol. 2004; 44: 740-9.
12. Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O, Frey A, Kaplan S, Krakover R, Caspi A, Vered Z, Cotter G. RITZ-5: randomized intravenous Tezosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol. 2003;41:204-10
13. Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, Krum H, Metra M, O’Connor CM, Parker JD, Torre-Amione G, Van Veldhuisen DJ, Frey A, Rainisio M, Kobrin I; VERITAS Investigators. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J 2005;150:46-53
14. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96:576-82.
15. Stiell IG, Hebert PC, Wells GA, Vandemheen KL, Tang AS, Higginson LA, Dreyer JF, Clement C, Battram E, Watpool I, Mason S, Klassen T, Weitzman BN. Vasopressin versus epinephrine for inhospital cardiac arrest: a randomised controlled trial. Lancet 2001;358:105-9.
16. Guzman JA, Rosado AE, Kruse JA. Vasopressin vs norepinephrine in endotoxic shock: systemic, renal, and splanchnic hemodynamic and oxygen transport effects. J Appl Physiol 2003; 95: 803-9.
This work is licensed under a Creative Commons Attribution 4.0 International License